Luxa Biotechnology
Pharmaceutical Manufacturing • 
United States • 1-10 Employees
Company overview
| Headquarters | United States |
| Phone number | +12014824093 |
| Websites | |
| NAICS | 3254 |
| Employees | 1-10 |
| Socials |
Key Contact at Luxa Biotechnology
Keith Dionne
Chief Executive Officer
Luxa Biotechnology Email Formats
Luxa Biotechnology uses 1 email format. The most common is {first initial}.{last name} (e.g., j.doe@luxabiotech.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@luxabiotech.com | 100% |
About Luxa Biotechnology
Luxa Biotechnology (LuxaBio) is a clinical-stage biotechnology company developing a novel adult RPE stem cell (RPESC) therapy for dry AMD. The proprietary adult RPESC-derived RPE stem cell product was developed at and licensed from the NSCI. LuxaBio is a partnership between the NSCI research institute and Y2 Solution, a Korean company to evaluate RPESC in a clinical trial to test the safety and efficacy of RPE progenitor stage progeny as a potential therapy for dry AMD. LuxaBio maintains a robust research program at NSCI to develop the RPESC as an effective, commercially viable cell product. The Phase 1/2a clinical trial of RPESC-RPE-4W for the Treatment of Dry Age-related Macular Degeneration includes the Cedars Sinai Biomanufacturing Center, Emmes, the University of Michigan Kellogg Eye Center, the National Eye Institute.
Luxa Biotechnology revenue & valuation
| Annual revenue | $513,330 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $1,700,000 |
| Total funding | $4,000,000 |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Luxa Biotechnology has 3 employees across 2 departments.
Departments
Number of employees
Saudi Arabia
Spain
United Kingdom
Canada
Frequently asked questions
4.8
40,000 users
